Clinical Trials Logo

Hyperemesis Gravidarum clinical trials

View clinical trials related to Hyperemesis Gravidarum.

Filter by:

NCT ID: NCT06266819 Recruiting - Clinical trials for Hyperemesis Gravidarum

The Effect of Mint Flavored Chewing Gum on Hyperemesis Gravidarum Nausea Vomiting Severity, Coping With Stress and Anxiety Level in Pregnants With Hyperemesis Gravidarum

Start date: January 15, 2024
Phase: N/A
Study type: Interventional

In the research planned as a randomized controlled study, the experimental groups will be administered routine hyperemesis gravidarum (HG) treatment as well as chewing mint-flavored gum, while the control group will only receive routine HG treatment and no intervention will be performed. This study aims to contribute to the literature by investigating the effect of chewing mint-flavored gum on the severity of nausea and vomiting, coping with stress, and anxiety levels due to hyperemesis gravidarum in pregnant women.

NCT ID: NCT06245811 Completed - Clinical trials for Hyperemesis Gravidarum

Inflammation Markers in Hyperemesis Gravidarum

Start date: January 20, 2022
Phase:
Study type: Observational

In this study, the relationship between the severity of hyperemesis gravidarum (HEG) disease and subclinical inflammatory factors such as Platelet Crit (PCT), Hemoglobin/red cell distribution width ratio (HRR), Neutrophil/lymphocyte ratio (NLR), was investigated.

NCT ID: NCT05927740 Completed - Corneal Dystrophy Clinical Trials

The Efficacy of Hyperemesis Gravidarum on Macular Thickness, Corneal Thickness and Intraocular Pressure in Pregnancy

Start date: March 10, 2020
Phase: N/A
Study type: Interventional

Aim Physiological changes in intraocular pressure as well as in the cornea and macula may occur during pregnancy. In the literature, there are limited data on ocular findings in hyperemesis gravidarum. Therefore, we have decided to investigate the effect of hyperemesis gravidarum on macular thickness, corneal thickness and intraocular pressure (IOP).

NCT ID: NCT05829473 Not yet recruiting - Clinical trials for Hyperemesis Gravidarum

The Effect of Guided Imagery and Diaphragmatic Breathing Exercise in Pregnant Women With Hyperemesis Gravidarum

Start date: April 30, 2023
Phase: N/A
Study type: Interventional

Objective: The aim of the researchers is to determine the effects of guided imagery and diaphragmatic breathing exercise application on nausea, vomiting severity, and anxiety level in pregnant with hyperemesis gravidarum. Methods: This study was planned as a single-blind randomized controlled experimental study. It is planned to be conducted with 180 pregnant women to be randomized in a university hospital in Southeastern Anatolia between April 2023 and August 2023. Data will be collected using the "Descriptive Information Form", "Nausea-Vomiting Severity Assessment Test During Pregnancy" and "Pregnancy-Related Anxiety Scale-R2". Keywords: Anxiety, Hyperemesis Gravidarum, Nausea-Vomiting, Guided Imagery, Diaphragmatic Breathing Exercise, Nursing,

NCT ID: NCT05452174 Enrolling by invitation - Pregnancy Clinical Trials

Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)

ESNAP
Start date: June 13, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this proposal is to conduct an early Phase 2 clinical trial to determine the acceptability, dosing, tolerability and safety of mirtazapine for severe nausea and vomiting of pregnancy (sNVP) that is not adequately responsive to current standard treatments. This plan mirrors clinical practice since commonly prescribed antiemetic/ antinauseant drugs will be tested for efficacy before treating with mirtazapine.

NCT ID: NCT05446025 Completed - Pregnancy Related Clinical Trials

The Levels of the Orexin, Galanin and aMSH and CART in Patients With Hyperemesis Gravidarum

Start date: June 26, 2022
Phase:
Study type: Observational [Patient Registry]

Hyperemesis gravidarum is a disease of unknown etiology that is frequently encountered in pregnant women and seriously impairs their quality of life. In the United States, hyperemesis gravidarum is the most common cause of hospitalizations in the first half of pregnancy and is second only to preterm labor for hospitalizations during pregnancy overall. The prevalence of hyperemesis gravidarum is approximately 0.3-3% of pregnancies and varies due to different diagnostic criteria and ethnic differences in study populations. According to the latest guidelines from the American College of Obstetricians and Gynecologists (ACOG) on nausea and vomiting during pregnancy, there is still no single accepted definition for hyperemesis gravidarum. The most commonly cited criteria for the diagnosis of hyperemesis gravidarum include persistent, unrelated to other causes, ketonuria, electrolyte abnormalities and acid-base disturbances, as well as weight loss. Weight loss is usually stated as at least 5% loss. In normal individuals, the appetite regulation center is the hypothalamus. Neuropeptides released from hypothalamic neurons play an important role in the regulation of nutrition by acting both in the hypothalamus and other appetite-regulating centers in the brain. Among the neuropeptides that are secreted by the central nervous system and peripheral organs and also play an important role in the regulation of energy and appetite, there are neuropeptides known as orexigenic neuropeptides, which reduce energy expenditure and increase appetite, as well as anorexigenic neuropeptides, which, on the contrary, reduce appetite and increase energy expenditure. It is known that disorders in these pathways cause pathologies in appetite and food intake in normal individuals. In our study, we plan to examine the levels of some neuropeptides in patients with hyperemesis gravidarum in order to investigate whether these pathways are affected or not. In this study, we aimed to investigate whether orexigenic neuropeptides (Orexin, Galanin) and anorexigenic neuropeptides (aMSH, CART) levels are associated with hyperemesis gravidarum.

NCT ID: NCT05244460 Recruiting - Clinical trials for Cannabis Hyperemesis Syndrome

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

DOPE
Start date: December 2, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.

NCT ID: NCT05175079 Completed - Clinical trials for Hyperemesis Gravidarum

Acupressure in Hyperemesis Gravidarum

Start date: October 1, 2016
Phase: N/A
Study type: Interventional

To examine the degree of nausea, vomiting between the acupressure and control group in women with hyperemesis gravidarum

NCT ID: NCT05098067 Completed - Clinical trials for Hyperemesis Gravidarum

Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy

Start date: May 24, 2022
Phase: Phase 2
Study type: Interventional

Between fifty and eighty percent of pregnant women experience nausea and vomiting in pregnancy making it one of the most common medical complications of pregnancy. Hyperemesis gravidarum is an extreme form of nausea and vomiting of pregnancy and results in evidence of acute starvation (i.e. large ketonuria), and weight loss (>5% of a woman's pre-pregnancy weight). Hyperemesis gravidarum is also surprisingly common. In fact, it is the second leading cause of preterm hospitalization during pregnancy, second only preterm labor. Hospitalization is often required because hyperemesis is frequently refractory to common anti-nausea medications. However, capsaicin cream, a potent TRPV1 agonist, commonly used to relieve muscular and neuropathic pain, may be able to reduce the symptoms of nausea and emesis in patients with nausea and vomiting of pregnancy. Smaller studies have demonstrated capsaicin to be both safe and effective when used to treat intraoperative nausea during cesarean delivery. To begin to address whether capsaicin cream could be used to reduce preterm admissions and shorten emergency room visits for hyperemesis, this study will randomize women presenting to the emergency room for nausea and vomiting to treatment with capsaicin cream as an adjunctive medication or routine care. The project will investigate the impact of capsaicin cream on hospital length of stay as well as representation for additional treatment. If effective, capsaicin cream has the potential not only to reduce emergency room visits, hospital admissions and overall health care costs, but also to drastically improve patient quality of life.

NCT ID: NCT05065567 Terminated - Clinical trials for Cyclic Vomiting Syndrome

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

Start date: August 30, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications, treatment failures and complications/side effects.